In conclusion, our findings reveal how PLK1-driven metabolic reprogramming enhances the adaptability of prostate cancer cells, particularly by modulating serine metabolism, glycolysis, and sphingolipid synthesis. This evidence concerns the gene PLK1 and prostate carcinoma.